문맥압 항진증과 합병증 : 간성뇌증 = Special Review in Portal Hypertension : Hepatic encephalopathy

다국어 초록 (Multilingual Abstract)

Hepatic encephalopathy, one of the major complications of cirrhosis, is a neuropsychiatric syndrome caused by accumulation of toxins in the central nervous system following dysfunction in liver detoxification. Various manifestations makes it difficulty to diagnose and categorize hepatic encephalopathy. For the consistency in diagnosis and staging of hepatic encephalopathy, standardized nomenclature regarding forms of hepatic encephalopathy was proposed recently. Due to the poor understanding of pathophysiology, effective prevention or treatment options are limited. Based on the theory that intestinal-derived ammonia plays major role in the development of hepatic encephalopathy, therapeutic approaches are directed at reducing intestinal bacterial production of ammonia and facilitating its elimination. Non-absorbable disaccharides, antibiotics such as rifaximin and L-ornithine-L-aspartate are main therapies for hepatic encephalopathy. Alternative therapies such as benzodiazepine receptor antagonists, branched-chain amino acids, sodium benzoate and acarbose have limited data supporting their use. Precipitating factors must be looked into carefully and corrected immediately because most patients are usually present with precipitating factors. Hepatic encephalopathy without precipitating factors shows poor prognosis and could be candidate of liver transplantation. (Korean J Med 75:27-36, 2008)

참고문헌 (Reference)

1 Marchesini G, "Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis" 23 : 1084-1092, 1996

2 Bianchi GP, "Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison" 233 : 385-392, 1993

3 Morgan MH, "Treatment of hepatic encephalopathy with metronidazole" 23 : 1-7, 1982

4 Michel H, "Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial" 79 : 207-211, 1980

5 Bircher J, "Treatment of chronic portal-systemic encephalopathy with lactulose" 1 : 890-892, 1966

6 Uribe M, "Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients" 25 : 924-928, 1980

7 Uribe M, "Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial" 76 : 1347-1351, 1979

8 Kircheis G, "Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study" 25 : 1351-1360, 1997

9 Hartmann IJ, "The prognostic significance of subclinical hepatic encephalopathy" 95 : 2029-2034, 2000

10 Norenberg MD, "The astrocyte in liver disease" 2 : 303-352, 1981

11 Rikkers L, "Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism" 75 : 462-469, 1978

12 Romero-Gómez M, "Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy" 96 : 2718-2723, 2001

13 Groeneweg M, "Subclinical hepatic encephalopathy impairs daily functioning" 28 : 45-49, 1998

14 Sushma S, "Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial" 16 : 138-144, 1992

15 Mousseau DD, "Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy" 162 : 192-196, 1993

16 Pedretti G, "Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial" 23 : 175-178, 1991

17 Pedretti G, "Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial" 23 : 175-178, 1991

18 Puxeddu A, "Rifaximin in the treatment of chronic hepatic encephalopathy" 13 : 274-281, 1995

19 Mullen KD, "Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy Aliment" 25 : 11-16, 2006

20 Bustamante J, "Prognostic significance of hepatic encephalopathy in patients with cirrhosis" 30 : 890-895, 1999

21 Christensen E, "Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors" 24 : 999-1006, 1989

22 Amodio P, "Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients" 35 : 37-45, 2001

23 Das A, "Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis" 16 : 531-535, 2001

24 Blei AT, "Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy" 96 : 1968-1976, 2001

25 Spahr L, "Pomier-- Layrargues G. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms" 24 : 1116-1120, 1996

26 Butterworth RF, "Pathophysiology of hepatic encephalopathy: a new look at ammonia" 17 : 221-227, 2002

27 Fabbri A, "Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy" 20 : 159-164, 1996

28 Stauch S, "Oral Lornithine- L-aspartate therapy of chronic hepatic encepha opathy: results of a placebo-controlled double-blind study" 28 : 856-864, 1998

29 Weissenborn K, "Neuropsychological charactererization of hepatic encephalopathy" 34 : 768-773, 2001

30 Stewart CA, "Neuroimaging in hepatic encephalopathy" 3 : 197-207, 2005

31 Atterbury CE, "Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial" 23 : 398-406, 1978

32 Hawkins RA, "Neomycin reduces the intestinal production of ammonia from glutamine" 368 : 125-134, 1994

33 Loft S, "Metronidazole pharmacokinetics in patients with hepatic encephalopathy" 22 : 117-123, 1987

34 Butterworth RF, "Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy" 4 : 259-267, 1995

35 Clausen MR, "Lactulose, disaccharides and colonic flora, clinical consequences" 53 : 930-942, 1997

36 Blanc P, "Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis" 15 : 222-228, 1992

37 James JH, "Hyperammo naemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy" 2 : 772-775, 1979

38 Abou-Assi S, "Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible" 109 : 52-70, 2001

39 Fitz JG, "Hepatic encephalopathy, in : Sleisenger and Fordtran's gastrointestinal and liver disease, 8th ed." Saunders Elsevier 2006

40 Fitz JG, "Hepatic encephalopathy, in : Sleisenger and Fordtran's gastrointestinal and liver disease, 8th ed." Saunders Elsevier 2006

41 Schafer DF, "Hepatic encephalopathy and the gamma-aminobutyric acid system" 1 : 18-20, 1982

42 Ferenci P, "Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998" 35 : 716-721, 2002

43 Weissenborn K, "Hecker Hartmut, Manns MP. The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy" 28 : 646-653, 1998

44 Schafer DF, "Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure" 102 : 870-880, 1983

45 Barbaro G, "Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study" 28 : 374-378, 1998

46 Miglio F, "Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial" 13 : 593-601, 1997

47 Fischer JE, "False neurotransmitters and hepatic failure" 2 : 75-80, 1971

48 Weber FL, Jr, "Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects" 82 : 213-217, 1982

49 Plauth M, "ESPEN guidelines for nutrition in liver disease and transplantation" 16 : 43-55, 1997

50 Merli M, "Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi)" 23 : 1041-1046, 1996

51 Kato A, "Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis in patients and establishment of diagnostic criteria – multicenter collaborative study in Japanese" 30 : 71-78, 2004

52 Berk DP, "Deafness complicating antibiotic therapy of hepatic encephalopathy" 73 : 393-396, 1970

53 Kircheis G, "Critical flicker frequency for quantification of low-grade hepatic encephalopathy" 35 : 357-366, 2002

54 백용한, "Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study" 연세대학교의과대학 46 (46): 399-407, 2005

55 Weissenborn K, "Clinical features of hepatic encephalopathy, in : Hepatology a textbook of liver disease" Saunders 435-438, 2003

56 Sama C, "Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label pilot study" 65 : 413-422, 2004

57 Tangerman A, "Cause and composition of foetor hepaticus" 343 : 483-, 1994

58 Charlton MR, "Branched chains revisited" 111 : 252-255, 1996

59 Norenberg MD, "Astrocytic-ammonia interactions in hepatic encephalopathy" 16 : 245-253, 1996

60 Uribe M, "Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial" 7 : 639-643, 1987

61 Gentile S, "A randomized controlled trial of acarbose in hepatic encephalopathy" 3 : 184-191, 2005

62 Saunders JB, "A 20-year prospective study of cirrhosis" 282 : 263-266, 1981

63 한철주, "2005년 대한학회 간경변 합병증 치료 가이드라인 간성뇌증의 치료 가이드라인" 11 : 150-163, 2005